Global Prophylactic Vaccines Market, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vector Vaccines, Other Vaccines), Disease (Pneumococcal Disease, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), Varicella, Human Papilloma Virus, COVID-19, Other Diseases), Administration (Intramuscular Route, Subcutaneous Route, Oral Route, Intravenous Injection, Other Administration Routes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Prophylactic Vaccines Market
The prophylactic vaccines market is expected to witness market growth at a rate of 25.00% in the forecast period of 2022 to 2029. Data Bridge Market Research report on prophylactic vaccines market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increase in the prevalence of various disorders globally is escalating the growth of prophylactic vaccines market.
A prophylactic vaccine, also known as preventative vaccine refers to the type of vaccines that introduce antigens into a person’s body. Creating antibodies for those antigens in the individual’s immune system, and becoming immune to the associated illness are the main purposes of the vaccines.
The increase in the need for preventive vaccines especially new COVID-19 vaccines across the globe acts as one of the major factors driving the growth of prophylactic vaccines market. The rise in the prevalence of various diseases among population such as measles, mumps, and rubella (MMR), varicella, pneumococcal disease, poliovirus, hepatitis, influenza, human papilloma virus, and COVID-19, among others accelerate the market growth. The rise in Research and Development across pharmaceutical companies for enhancing different types of preventive vaccines, and increase in the merge and collaborations further influence the market. Additionally, growth in awareness, surge in healthcare expenditure, development in technology and rise in government initiatives positively affect the prophylactic vaccines market. Furthermore, development in the vaccines extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, long time approval for drugs is expected to obstruct the market growth. The stringent regulations are projected to challenge the prophylactic vaccines market in the forecast period of 2022-2029.
This prophylactic vaccines market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info prophylactic vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Prophylactic Vaccines Market Scope and Market Size
The prophylactic vaccines market is segmented on the basis of vaccine type, disease, administration, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of route of vaccine type, the prophylactic vaccines market is segmented into live/attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vector vaccines, and other vaccines.
- On the basis of disease, the prophylactic vaccines market is segmented into pneumococcal disease, poliovirus, hepatitis, influenza, measles, mumps, and rubella (MMR), varicella, human papilloma virus, COVID-19 and other diseases.
- On the basis of disease, the prophylactic vaccines market is segmented into intramuscular route, subcutaneous route, oral route, intravenous injection, and other administration routes.
- On the basis of distribution channel, the prophylactic vaccines market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
- On the basis of end-users, the prophylactic vaccines market is segmented into hospitals, homecare, specialty clinics and others.
Prophylactic Vaccines Market Country Level Analysis
The prophylactic vaccines market is analyzed and market size information is provided by country, vaccine type, disease, administration, distribution channel and end-users as referenced above.
The countries covered in the global prophylactic vaccines market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the prophylactic vaccines market due to the presence of leading healthcare systems in the world and the vaccination coverage within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the surge in investments in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The prophylactic vaccines market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Prophylactic Vaccines Market Share Analysis
The prophylactic vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related prophylactic vaccines market.
Some of the major players operating in the prophylactic vaccines market are Bharat Biotech., Ceva, GlaxoSmithKline plc, Grifols, S.A, Zoetis Services LLC., Virbac. Sanofi, Merck & Co., Inc., Emergent BioSolutions Inc, Integrated BioTherapeutics, Inc., Abbott, Avalon Pharma Private Limited, Haffkine Bio-Pharmaceutical Corporation Ltd and Pfizer Inc., among others.
SKU-